In male Sprague–Dawley rats, intraperitoneal Varenicline pretreatment reduced the increase associated with nicotine omission in Cluster B but had no significant effect in Cluster A, compared with omission without pretreatment. In male Wistar rats, intraperitoneal Varenicline affected active nose pokes, with post hoc analyses showing significantly reduced nicotine self-administration compared with vehicle. In male Wistar rats chronically drinking ethanol, Varenicline microinfusion into the NAc core-shell border did not affect ethanol or water intake compared with vehicle. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Varenicline and nicotine omission in Cluster B rats
Animal study · Male Sprague–Dawley rats; n = 26 Cluster B [1]
Male Sprague–Dawley rats in Cluster B received Varenicline at 1 mg/kg free base by intraperitoneal injection. Varenicline pretreatment reduced the increase associated with nicotine omission compared with nicotine omission without Varenicline.
Conditions shared by the study groups
- Route
- intraperitoneal (i.p.) injection
- Treatment course
- 30 min before the session began; session 23
- Vehicle
- sterile 0.9% physiological saline
- Varenicline 1 mg/kg free base
- Model: Male Sprague–Dawley rats; n = 26 Cluster B
Methods and source locations
Compound reported in the paper: Varenicline
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Animals (S1); Materials and methods > Nicotine intravenous self-administration (S17); Materials and methods > Nicotine intravenous self-administration > Self-administration standard protocol (S22); Materials and methods > Behavioral characterization of the identified clusters (S51, S54, S55); Results > Psychopharmacological features of clusters A and B > Varenicline effect on nicotine seeking in Clusters A and B (S155); Fig. 1 legend (S157); Fig. 4 legend (S170)
Global effect of nicotine omission: Global effect of nicotine omission; comparator: nicotine omission without (NicOm) — Results > Psychopharmacological features of clusters A and B > Varenicline effect on nicotine seeking in Clusters A and B (S155); Fig. 4 legend (S170)
Varenicline 1 mg/kg free base · Materials and methods > Behavioral characterization of the identified clusters (S51, S54, S55); Results > Psychopharmacological features of clusters A and B > Varenicline effect on nicotine seeking in Clusters A and B (S155)
Varenicline and nicotine self-administration in Wistar rats
Animal study · Male Wistar rats [2]
Male Wistar rats received intraperitoneal Varenicline before testing. Compared with vehicle, 1.5 mg/kg and 2.5 mg/kg significantly reduced nicotine self-administration.
Conditions shared by the study groups
- Route
- intraperitoneally
- Treatment course
- 30 min before testing
- Vehicle
- 1% methylcellulose–5% mannitol solution
- Varenicline 0.5, 1.5 and 2.5 mg/kg
- Model: Male Wistar rats
Methods and source locations
Compound reported in the paper: Varenicline
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Animals (S1, S3); Methods > Apparatus and behavioural procedure > Self-administration (S11); Methods > Drugs (S61, S62); Results > Experiment 1: nicotine self-administration (S70, S72)
total number of active nose pokes: total number of active nose pokes; comparator: vehicle — Results > Experiment 1: nicotine self-administration (S72)
Varenicline 0.5, 1.5 and 2.5 mg/kg · Methods > Drugs (S62); Results > Experiment 1: nicotine self-administration (S72)
Ethanol and Water Intake Following Local Microinfusion
Animal study · Male Wistar rats; rats chronically drinking ethanol in the two-bottle choice model (n = 8–12 animals per brain region) [3]
Varenicline or vehicle infusions did not affect water intake (30 min, 4 and 24 h) or ethanol intake (4 and 24 h).
Conditions shared by the study groups
- Route
- Microinfusion; into the NAc core-shell border
- Treatment course
- for 4 min; drinking sessions commenced 10 min after infusions; 1 week between treatments
- Vehicle
- 10% potassium phosphate buffer/90% isotonic saline
- Varenicline 2 µg
- Model: Male Wistar rats; rats chronically drinking ethanol in the two-bottle choice model (n = 8–12 animals per brain region)
Methods and source locations
Compound reported in the paper: Varenicline
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Drugs and chemicals (S5); Methods > Animals and housing (S8); Methods > Ethanol drinking paradigms (S12); Methods > Surgical procedures (S16); Methods > Microinjection procedures (S27, S28, S29); Results > Microinfusion of varenicline (S58, S59); Table 1 legend (S100); Table 1 (T1.h1, T1.h2, T1.r5, T1.r8)
Ethanol intake (mL); 4 h: Ethanol intake (mL); 4 h; comparator: Vehicle; 2.1 ± 0.1 mL — Table 1 legend (S100); Table 1 (T1.h1, T1.h2, T1.r5, T1.r8)
Varenicline 2 µg · Methods > Microinjection procedures (S27, S28, S29); Results > Microinfusion of varenicline (S59); Table 1 legend (S100); Table 1 (T1.h1, T1.h2, T1.r8)
Varenicline and nicotine omission in Cluster A rats
Animal study · Male Sprague–Dawley rats; n = 29 Cluster A [1]
Male Sprague–Dawley rats in Cluster A received Varenicline at 1 mg/kg free base by intraperitoneal injection. Varenicline pretreatment had no significant effect on the global effect of nicotine omission compared with nicotine omission without Varenicline.
Conditions shared by the study groups
- Route
- intraperitoneal (i.p.) injection
- Treatment course
- 30 min before the session began; session 23
- Vehicle
- sterile 0.9% physiological saline
- Varenicline 1 mg/kg free base
- Model: Male Sprague–Dawley rats; n = 29 Cluster A
Methods and source locations
Compound reported in the paper: Varenicline
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Animals (S1); Materials and methods > Nicotine intravenous self-administration (S17); Materials and methods > Nicotine intravenous self-administration > Self-administration standard protocol (S22); Materials and methods > Behavioral characterization of the identified clusters (S51, S54, S55); Results > Psychopharmacological features of clusters A and B > Varenicline effect on nicotine seeking in Clusters A and B (S155); Fig. 1 legend (S157); Fig. 4 legend (S170)
Global effect of nicotine omission: Global effect of nicotine omission; comparator: nicotine omission without (NicOm) — Results > Psychopharmacological features of clusters A and B > Varenicline effect on nicotine seeking in Clusters A and B (S155); Fig. 4 legend (S170)
Varenicline 1 mg/kg free base · Materials and methods > Behavioral characterization of the identified clusters (S51, S54, S55); Results > Psychopharmacological features of clusters A and B > Varenicline effect on nicotine seeking in Clusters A and B (S155)